<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>丰硕创投 | wechat-feeds</title><link>http://MzA3ODc3MDk2Nw.favicon.privacyhide.com/favicon.ico</link><description>聚焦医药投研</description><managingEditor> (hellodword)</managingEditor><pubDate>Wed, 09 Jun 2021 11:46:58 +0800</pubDate><image><url>http://MzA3ODc3MDk2Nw.favicon.privacyhide.com/favicon.ico</url><title>丰硕创投 | wechat-feeds</title><link>http://MzA3ODc3MDk2Nw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>潜在的龙头，腾盛博药差异化的发展模式</title><link>https://mp.weixin.qq.com/s/ZmaLvhdbwmyiO1QdoV2P_w</link><description></description><content:encoded><![CDATA[潜在的龙头，腾盛博药差异化的发展模式]]></content:encoded><pubDate>Wed, 09 Jun 2021 10:44:23 +0800</pubDate></item><item><title>如何看信达引进ROS1/NTRK双靶点抑制剂Taletrectinib？</title><link>https://mp.weixin.qq.com/s/OfXXFrTAVuPgBAjTj7Rn1Q</link><description></description><content:encoded><![CDATA[如何看信达引进ROS1/NTRK双靶点抑制剂Taletrectinib？]]></content:encoded><pubDate>Mon, 07 Jun 2021 17:41:25 +0800</pubDate></item><item><title>AAV载体，在基因治疗时代大放异彩！</title><link>https://mp.weixin.qq.com/s/ydDm3rTCd9FyjTdCRAJRLw</link><description></description><content:encoded><![CDATA[AAV载体，在基因治疗时代大放异彩！]]></content:encoded><pubDate>Fri, 04 Jun 2021 15:44:21 +0800</pubDate></item><item><title>干货分享|如何做好医药行业研究？</title><link>https://mp.weixin.qq.com/s/Qd2GjPHM2ZtDmuOr4qNEwQ</link><description></description><content:encoded><![CDATA[干货分享|如何做好医药行业研究？]]></content:encoded><pubDate>Wed, 02 Jun 2021 10:13:33 +0800</pubDate></item><item><title>PI3Kδ抑制剂优于BTK抑制剂？！</title><link>https://mp.weixin.qq.com/s/I38whBv5fuqdVlNpXVXqOA</link><description></description><content:encoded><![CDATA[PI3Kδ抑制剂优于BTK抑制剂？！]]></content:encoded><pubDate>Tue, 01 Jun 2021 16:42:33 +0800</pubDate></item><item><title>盘点拿中国临床数据申报美国上市的企业</title><link>https://mp.weixin.qq.com/s/yuRVoqKc0c9mJeRC5UQhJQ</link><description></description><content:encoded><![CDATA[盘点拿中国临床数据申报美国上市的企业]]></content:encoded><pubDate>Wed, 26 May 2021 10:57:51 +0800</pubDate></item><item><title>AI公司Recursion：引领图像识别药物开发新潮流</title><link>https://mp.weixin.qq.com/s/NthuO5n1UyUnwbiVO3beCQ</link><description></description><content:encoded><![CDATA[AI公司Recursion：引领图像识别药物开发新潮流]]></content:encoded><pubDate>Tue, 25 May 2021 11:20:10 +0800</pubDate></item><item><title>PI3Kδ靶点—国内药企雄起的机遇</title><link>https://mp.weixin.qq.com/s/ygFU9eNrMWtI4hewjyUrpA</link><description></description><content:encoded><![CDATA[PI3Kδ靶点—国内药企雄起的机遇]]></content:encoded><pubDate>Mon, 24 May 2021 17:12:08 +0800</pubDate></item><item><title>作用于表观遗传学的共价药物---menin抑制剂</title><link>https://mp.weixin.qq.com/s/ivFhVwl6lpGc-O-tlxVrng</link><description></description><content:encoded><![CDATA[作用于表观遗传学的共价药物---menin抑制剂]]></content:encoded><pubDate>Tue, 18 May 2021 15:55:33 +0800</pubDate></item><item><title>手握重磅IL-4Rα药物的康诺亚，成立5年即IPO</title><link>https://mp.weixin.qq.com/s/8c4L9xHCQgbzRgu0gNT98Q</link><description></description><content:encoded><![CDATA[手握重磅IL-4Rα药物的康诺亚，成立5年即IPO]]></content:encoded><pubDate>Tue, 11 May 2021 16:32:57 +0800</pubDate></item></channel></rss>